PMID- 9783696
OWN - NLM
STAT- MEDLINE
DCOM- 19981210
LR  - 20061115
IS  - 0146-6615 (Print)
IS  - 0146-6615 (Linking)
VI  - 56
IP  - 3
DP  - 1998 Nov
TI  - Neutralization of HIV-1 subtypes: implications for vaccine formulations.
PG  - 264-8
AB  - More than 20.8 million people are infected with HIV in sub-Saharan Africa, with 
      South Africa having one of the fastest growing HIV-1 epidemics, where an 
      estimated 2.4 million people were infected. Thirty-two sera from 25 patients were 
      tested for their ability to neutralize HTLV-IIIB (IIIB) and four primary isolates 
      representing subtypes B, C, D, and a recombinant gag C/env B type. A CEM-SS cell 
      line-based assay was used and the neutralizing titer was defined as the 
      reciprocal of the highest dilution giving a 50% reduction in p24 antigen 
      production. All isolates were neutralized better by subtype-specific sera, except 
      for the C4714 strain, which was neutralized by both subtype B and C sera. C4714 
      was neutralized by 18/25 (72%) sera, IIIB by 19/32 (59%) sera, D482 by 7/31(23%) 
      sera, B3245 by 6/29 (21%) sera, and the recombinant B/C1491 isolate by 4/25 (16%) 
      sera. Five sera were unable to neutralize any of the isolates. The V3 region of 
      the isolates used in the neutralization assay was amplified by PCR, directly 
      sequenced, and analyzed to reveal variability between the consensus HIV-1 
      sequences and the isolates. HIV-1 strain C4714 was neutralized more effectively 
      with the sera tested than the IIIIB laboratory strain. Variability in the amino 
      acid sequence of the V3 region, which can alter the conformation of the V3 loop 
      secondary structure, can influence the neutralization of a particular viral 
      isolate. Vaccine formulations should be broadened to include multiple subtypes, 
      especially C subtypes, which is rapidly spreading worldwide.
FAU - Smith, T L
AU  - Smith TL
AD  - Department of Medical Virology, University of Stellenbosch and Tygerberg 
      Hospital, South Africa.
FAU - van Rensburg, E J
AU  - van Rensburg EJ
FAU - Engelbrecht, S
AU  - Engelbrecht S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (AIDS Vaccines)
RN  - 0 (HIV Antibodies)
RN  - 0 (HIV Core Protein p24)
RN  - 0 (HIV Envelope Protein gp120)
RN  - 0 (HIV envelope protein gp120 (305-321))
RN  - 0 (Peptide Fragments)
SB  - IM
MH  - AIDS Vaccines/*immunology
MH  - Amino Acid Sequence
MH  - Cell Line
MH  - Cells, Cultured
MH  - HIV Antibodies/*immunology
MH  - HIV Core Protein p24/analysis
MH  - HIV Envelope Protein gp120/chemistry/*immunology
MH  - HIV Infections/immunology
MH  - HIV-1/classification/*immunology/isolation & purification
MH  - Humans
MH  - Molecular Sequence Data
MH  - Neutralization Tests
MH  - Peptide Fragments/chemistry/*immunology
MH  - Polymerase Chain Reaction
EDAT- 1998/10/23 02:01
MHDA- 2000/06/20 09:00
CRDT- 1998/10/23 02:01
PHST- 1998/10/23 02:01 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1998/10/23 02:01 [entrez]
AID - 10.1002/(SICI)1096-9071(199811)56:3<264::AID-JMV15>3.0.CO;2-E [pii]
PST - ppublish
SO  - J Med Virol. 1998 Nov;56(3):264-8.